Instagram
Mount Sinai has launched the AI Small Molecule Drug Discovery Center at the Icahn School of Medicine, integrating artificial intelligence with cutting-edge chemistry and biology to accelerate drug development. By leveraging machine learning, the Center will design, optimize, and predict new drug candidates with unprecedented speed and precision. This AI-driven approach will enable researchers to navigate vast chemical landscapes more efficiently, significantly reducing the time and cost associated with traditional drug discovery.
The Center will focus on developing treatments for diseases with urgent unmet needs, including cancer, metabolic disorders, and neurodegenerative diseases. By combining AI-driven insights with Mount Sinai’s expertise in biomedical research, the initiative aims to revolutionize how new medicines are identified and brought to patients.
